Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120

BACKGROUND: Two randomized, double-blind, placebo-controlled trials (EPPIC-1 and EPPIC-2) investigated the efficacy and safety of AST-120, an oral spherical carbon adsorbent, in adults with chronic kidney disease (CKD). While the benefit of adding AST-120 to standard therapy was not supported by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulman, Gerald, Berl, Tomas, Beck, Gerald J., Remuzzi, Giuseppe, Ritz, Eberhard, Shimizu, Miho, Kikuchi, Mami, Shobu, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838144/
https://www.ncbi.nlm.nih.gov/pubmed/28741050
http://dx.doi.org/10.1007/s10157-017-1447-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838144/
https://www.ncbi.nlm.nih.gov/pubmed/28741050
http://dx.doi.org/10.1007/s10157-017-1447-0

Ejemplares similares